Citadel Advisors
MPLT

Citadel Advisors’s MapLight Therapeutics MPLT Stock Holding History

Citadel Advisors’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$609K Buy
+17,000
New +$489K ﹤0.01% 9394

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's MPLT Position: Q2 2026 in Review

Citadel Advisors opened a new position in MapLight Therapeutics (MPLT) in Q2 2026: 25,751 shares worth $923K. The stake represents ﹤0.01% of the portfolio and ranks #8396 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in MPLT as recently as Q4 2025.

Citadel Advisors first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.34M in Q4 2025. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Citadel Advisors held 25,751 shares of MapLight Therapeutics worth $923K as of Q2 2026.
  • MapLight Therapeutics was a new Citadel Advisors position in Q2 2026.
  • MapLight Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8396 holding.
  • Citadel Advisors first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Citadel Advisors's MapLight Therapeutics position peaked at $3.34M in Q4 2025.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.